Effects on the endocrine system of long-term treatment with the luteinizing hormone-releasing hormone agonist leuprolide in patients with benign prostatic hyperplasia

Scandinavian Journal of Clinical and Laboratory Investigation

Volumn 56, Issue 4, 1996, Pages 319-325

  Eri, L M ^a   Haug, E ^b   Tveter, K J ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b AKER UNIVERSITY HOSPITAL   (Norway)

Author keywords

adrenal cortex hormones; gonadorelin; prostatic hypertrophy; sex hormones

Indexed keywords

ANDROSTENEDIONE; ESTRADIOL; ESTRONE; FOLLITROPIN; GONADORELIN AGONIST; LEUPRORELIN; LUTEINIZING HORMONE; PRASTERONE SULFATE; PROLACTIN; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE;

AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; HYPERPLASIA; INTRAMUSCULAR DRUG ADMINISTRATION; MALE; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; SUSTAINED RELEASE PREPARATION;

EID: 0029967119     PISSN: 00365513     EISSN: None     Source Type: Journal    
DOI: 10.3109/00365519609090583     Document Type: Article

References (22)

1. Koutsilieris M, Tolis G. Gonadotropin-releasing hormone agonistic analogues in the treatment of advanced prostatic carcinoma. Prostate 1983; 4: 569-77.
2. Sharifi R, Soloway M and The Leuprolide Study Group. Clinical study of leuprolide depot formulation in the treatment of advanced prostate cancer J Urol 1990; 143; 68-71.
3. Schroeder FH, Lock TMTW, Chadha DR, Debruyne FMJ, Karthaus HFM, de Jong FH, et al. Metastatic cancer of the prostate managed with buserelin versus buserelin plus cyproterone acetate. J Urol 1987; 137:912-8.
4. Peters CA, Walsh PC. The effect of nafarelin acetate, a luteinizing-hormone-releasing hormone agonist, on benign prostatic hyperplasia. N Engl J Med 1987; 317: 599-617.
5. Gabrilove JL, Levine AC, Kirschenbaum A, Droller M. Effect of long-acting gonadotropinreleasing hormone analog (leuprolide) therapy on prostatic size and symptoms in 15 men with benign prostatic hypertrophy. J Clin Endocrinol Metab 1989; 69: 629-32.
6. Matzkin H, Chen J, Lewysohn O, Braf Z. Treatment of benign prostatic hypertrophy by a long-acting gonadotropin-releasing hormone analogue: 1-year experience. J Urol 1991; 145: 309-12.
7. Eri LM, Tveter KJ. A prospective, placebocontrolled study of the luteinizing hormone-releasing hormone agonist leuprolide as treatment for patients with benign prostatic hyperplasia. J Urol 1993; 150: 359-64.
8. Mahler C, Verhelst J, Chaban M, Denis L. Prolactin and pituitary gonadotropin values and responses to acute luteinizing hormone-releasing hormone (LHRH) challenge in patients having long-term treatment with a depot LHRH analogue. Cancer 1991; 67: 557-9.
9. Findling JW, Tyrrell JB. Anterior pituitary gland. In: Greenspan FS, editor. Basic and clinical endocrinology, 3rd ed. Englewood Cliffs, New Jersey: Prentice Hall, 1991: 79-132.
10. Bartsch W, Horst H-J, Becker H, Nehse G. Sex hormone binding globulin binding capacity, testosterone, 5 alpha-dihydrotestosterone, oestradiol and prolactin in plasma of patients with prostatic carcinoma under various types of hormonal treatment. Acta Endocrinol (Copenh), 1977; 85: 650-64.
11. Røhl HF, Beuke H-P. Effect of orchidectomy on serum concentrations of testosterone and dihydrotestosterone in patients with prostatic cancer. Scand J Urol Nephrol 1992; 26: 11-14.
12. Rizzo M, Mazzei T, Mini E, Periti P. Leuprorelin acetate depot in advanced prostatic cancer: a phase II muticentre trial. J Int Med Res 1990; 18 suppl 1: 114-25.
13. O'Brien A, Hibberd M. Clinical efficacy and safety of a new leuprorelin acetate depot formulation in patients with advanced prostatic cancer. J Int Med Res 1990; 18 Suppl 1: 57-68.
14. Giraud B. Interim report of a large French multicentre study of efficacy and safety of 3.75mg leuprorelin depot in metastatic prostatic cancer. J Int Med Res 1990; 18 Suppl 1: 84-9.
15. Matzkin H, Kaver I, Lewysohn O, Ayalon D, Braf Z. The role of increased prolactin levels under GnRH analogue treatment in advanced prostatic carcinoma. Cancer 1988; 61: 2187-91.
16. Siegel YI, Korczak D, Lindner A. Serum prolactin levels in patients treated with a gonadotropin-releasing hormone analogue for adenocarcinoma of the prostate. Eur Urol 1991; 19: 16-8.
17. Nokin J, Vekemans M, L'Hermite M, Robyn C. Circadian periodicity of serum prolactin concentration in man. Br Med J 1972; 3: 561-2.
18. Tyrrell JB, Aron DC, Forsham PH. Glucocorticoids and adrenal androgens. In: Greenspan FS, editor. Basic and clinical endocrinology, 3rd ed. Englewood Cliffs, New Jersey: Prentice Hall, 1991: 323-62.
19. Lukkarinen O, Hammond GL, Kontturi M. Vihko R. Long-term effects of endocrine treatment in advanced prostatic carcinoma patients. Invest Urol 1980; 17: 328-31.
20. Carlström K, Collste L, Eriksson A, Henriksson P, Pousette A, Stege R, et al. A comparison of androgen status in patients with prostatic cancer treated with oral and/or parenteral estrogens or by orchidectomy. Prostate 1989; 14: 177-82.
21. Lunglmayr G, Girsch E, Meixner EM, Viehberger G, Bieglmayer C. Effects of long term GnRH analogue treatment on hormone levels and spermatogenesis in patients with carcinoma of the prostate. Urol Res 1988; 16: 315-19.
22. Braunstein DG. Testes. In Greenspan FS, editor: Basic and clinical endocrinology, 3rd ed. Englewood Cliffs, New Jersey: Prentice Hall. 1991: 407-41.